Characterization of intact hemoglobin and oxaliplatin interaction by nanoelectrospray ionization tandem mass spectrometry

Clinical Chemistry

Volumn 51, Issue 12, 2005, Pages 2274-2281

  Peng, Jun ^a   Mandal, Rupasri ^a   Sawyer, Michael ^a   Li, Xing Fang ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; OXALIPLATIN;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TOLERABILITY; ELECTROSPRAY MASS SPECTROMETRY; ERYTHROCYTE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; METHODOLOGY; SIDE EFFECT;

COLORECTAL NEOPLASMS; ERYTHROCYTES; HEALTH; HEMOGLOBINS; HUMANS; ORGANOPLATINUM COMPOUNDS; PROTEIN BINDING; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 28044465145     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.051847     Document Type: Article

References (40)

1. Rixe O, Ortuzar W, Alvarez A, Parker R, Reed E, Paul K, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol 1996;52:1855-65.
2. Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res 1988;48:9-13.
3. Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995;15:393-8.
4. Dunn TA, Schmoll HJ, Gruenwald V, Bokemeyer C, Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997;15:109-14.
5. Cleare MJ, Hydes PC, Molerbi BW, Watkins DM. Antitumor platinum complexes: relationship between chemical properties and activity. Biochimie (Paris) 1978;60:835-50.
6. Burchenal JH, Irani G, Kern K, Lokys L, Turkevich J. 1,2- Diaminocyclohexane platinum derivatives of potential clinical value. Recent Results Cancer Res 1980;74:146-55.
7. Graham J, Muhsin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov 2004;3:11-2.
8. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002;42:317-25.
9. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005;31:90-105.
10. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993;53:5970-6.
11. Levi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000;38:1-21.
12. Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000;60:895-924.
13. Gamelin E, Bouil AL, Boisdron-Celle M, Turcant A, Delva R, Cailleux A, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 1997;3:891-9.
14. Allain P, Heudi O, Cailleux A, Le Bouil A, Larra F, Boisdron-Celle M, et al. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 2000;28:1379-84.
15. Garufi C, Vaglio S, Brienza S, Conti L, D'Attino RM, Girelli G, et al. Immunohemolytic anemia following oxaliplatin administration [Letter]. Ann Oncol 2000;11:497.
16. Kern W, Braess J, Bottger B, Kaufmann CC, Hiddemann W, Schleyer E. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin Cancer Res 1999;5:761-5.
17. Espinosa E, Feliu J, Zamora P, Baron MG, Sanchez JJ, Ordonez A, et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 1995;12:67-76.
18. Appleton TG. Donor atom preferences in complexes of platinum and palladium with amino acids and related molecules. Coord Chem Rev 1997;166:313-59.
19. Allain P, Berre S, Mauras Y, Le Bouil A, Evaluation of inductively coupled plasma mass spectrometry for the determination of platinum in plasma. Biol Mass Spectrom 1992;21:141-3.
20. Pruden EL, Sigaard-Andersen O, Teitz NW. Blood gases and pH. In: Burtis CA, Ashwood ER, eds. Tietz textbook of clinical chemistry, 2nd ed. Philadelphia: WB Saunders, 1994:1375-410.
21. Rai DK, Landin B, Alvelius G, Griffiths WJ. Electrospray tandem mass spectrometry of intact β-chain hemoglobin variants. Anal Chem 2002;74:2097-102.
22. Riggs A. Preparation of blood hemoglobins of vertebrates. Methods Enzymol 1981;76:5-29.
23. Light-Wahl KJ, Schwartz BL, Smith RD. Observation of the noncovalent quaternary associations of proteins by electrospray ionization mass spectrometry. J Am Chem Soc 1994;116:5271-8.
24. Schmidt A, Karas M. The influence of electrostatic interactions on the detection of heme-globin complexes in ESI-MS. J Am Soc Mass Spectrom 2001;12:1092-8.
25. Griffith WP, Kaltashov IA. Highly asymmetric interactions between globin chains during hemoglobin assembly revealed by electrospray ionization mass spectrometry. Biochemistry 2003;42:10024-33.
26. Hagrman D, Goodisman J, Souid AK. Kinetic study on the reactions of platinum drugs with glutathione. J Pharmacol Exp Ther 2004;308:658-66.
27. Timerbaev AR, Aleksenko SS, Polec-Pawlak K, Ruzik R, Semenova O, Hartinger CG, et al. Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin. Electrophoresis 2004;25: 1988-95.
28. Ivanov AI, Christodoulou J, Parkinson JA, Barnham KJ, Tucker A, Woodrow J, et al. Cisplatin binding sites on human albumin. J Biol Chem 1998;273:14721-30.
29. Gibson D, Costello CE. A mass spectral study of the binding of the anticancer drug cisplatin to ubiquitin. Eur J Mass Spectrom 1999;5:501-10.
30. Peleg-Shulman T, Najajreh Y, Gibson D. Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles. J Inorg Biochem 2002;91:306-11.
31. Allardyce CS, Dyson PJ, Coffey J, Johnson N. Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin. Rapid Commun Mass Spectrom 2002;16:933-5.
32. Mandal R, Teixeira C, Li XF. Studies of cisplatin and hemoglobin interactions using nanoelectrospray mass spectrometry and liquid chromatography with inductively-coupled plasma mass spectrometry. Analyst 2003;128:629-34.
33. Mandal R, Kalke R, Li XF. Interaction of oxaliplatin, cisplatin and carboplatin with hemoglobin and the resulting release of a heme group. Chem Res Toxicol 2004;17:1391-7.
34. Albert SN, Jain SC, Shibuya J, Albert CA. Measuring hematocrit. In: The hematocrit in clinical practice. Springfield, IL: CC Thomas, 1965:7-10.
35. s) in sickle cell disease. Anal Biochem 2001;298:76-82.
36. Douglas DJ, French JB. Collisional focusing effects in radio frequency quadrupoles. J Am Soc Mass Spectrom 1992;3:398-408.
37. Krutchinsky AN, Chernushevich IV, Spicer VL, Ens W, Standing KG. Collisional damping interface for an electrospray ionization time-of-flight mass spectrometer. J Am Soc Mass Spectrom 1998;9:569-79.
38. Tito MA, Tars K, Valegard K, Hajdu J, Robinson CV. Electrospray time-of-flight mass spectrometry of the intact MS2 virus capsid. J Am Chem Soc 2000;122:3550-1.
39. Li XF, Mandal R, Peng J, Kalke R, Sawyer M. Nanospray mass spectrometry and HPLC/ICPMS studies of oxaliplatin to blood proteins and clinical implications [Abstract]. In: Proceedings of the 52nd ASMS Conference on Mass Spectrometry and Allied Topics, May 23-27, 2004, Nashville, Tennessee.
40. Raymond E, Faivre S, Chaney S, Woynaarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-35.